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Introduction
The proportion of patients who respond to available treatments 
for psychological and chronic pain disorders is often low. For 
example, in major depression, roughly 40% of individuals 
experience a ‘clinically significant’ response (decrease in symptom 
severity score above some minimum value) over the course of 
treatment (e.g. 1,2). Similarly, a recent meta-analysis of available 
pharmacotherapies for neuropathic pain found estimates of ‘number 
needed to treat’ (number of patients needed to be treated to prevent 
one additional adverse clinical outcome) for effective treatments 
ranged from 4–10, indicating poor response rates3. For patients, 
this often means a lengthy process of cycling through different 
treatment options, in a sequence that may be significantly 
influenced by non-clinical concerns (e.g. relative drug cost, 
therapist availability, local health authority guidelines), and where 
there may be inadequate data on the safety and effectiveness of 
switching regimes (e.g. 4). For psychological conditions, this 
process can be particularly lengthy, given the significant period 
of time before common pharmacological treatments are expected 
to take effect (e.g. 4–6 weeks to conclude a particular drug 
treatment is ineffective,4). Together, this results in a substantial 
burden of suffering and disability for individuals with a diagnosis 
of these disorders, before (if) an effective treatment option can be 
found.
It is generally assumed that differential response to a particular 
treatment across individuals can be at least partially explained by 
patient heterogeneity within a certain diagnostic category – i.e. 
that individuals who present to the clinic with similar sets of 
symptoms may have different underlying pathologies. This seems 
a particularly reasonable assumption in the case of both mental 
health disorders and chronic pain, as diagnosis is often made purely 
on the basis of self-reported symptom checklists, and our lack 
of knowledge into the aetiology of these conditions means we have 
little opportunity for differential diagnosis. Indeed, in the case 
of psychiatric disorders, such as depression, diagnosis can often 
be made on the basis of directly contradictory symptom reports 
(e.g. sleeping too much vs sleeping too little), and there may  be 
many different ways to meet diagnostic criteria (e.g. 227 possible 
symptom combinations for major depressive disorder, according 
to DSM-IV5). Similarly, even patients with a diagnosis of a 
particular pain condition are likely to have distinct patterns of 
nervous system damage, involving multiple pathways (e.g. 6), and 
definitions of chronic pain itself can vary dramatically across 
research groups and clinical centres7.
Even if we lack insight into pathological mechanisms, it seems 
likely that if we are able to use some kind of predictive method 
to direct individuals towards treatments that are likely to be more 
effective for them – then even a small increase in the resulting 
response rate could potentially have a large effect on disease 
burden for individual patients. There has therefore recently 
been great interest in doing just this for psychiatric data, via 
application of supervised learning methods to large datasets of 
individual clinical predictors and treatment response data (see 8 
for an excellent recent review of potential clinical advantages 
 and best methodological practice in this area).
The current gold standard approach is firstly to define a set of 
features and targets for various machine learning algorithms 
to train on. In this context, features are individual difference 
variables that may potentially relate to future treatment outcome 
(clinical, demographic, physiological, genetic, behavioural, etc. 
information). The target variable (that the algorithm must learn 
to predict) is usually a binary category label, such as ‘responder’ 
or ‘non-responder’ (whether or not an individual has exhibited 
symptom improvement above some threshold level, following 
a particular course of treatment). Various supervised learning 
algorithms can then be trained on this labelled dataset (ideally 
using a rigorous cross-validated approach), and assessed in terms 
of their predictive accuracy on independent ‘unseen’ (during 
model training) data. Finally, the best model can be brought 
forward to a randomised controlled trial framework, where 
treatment allocation by current clinical guidelines could be 
compared to algorithm-assisted treatment assignment8.
This approach is highly attractive, as the potential clinical 
gains from even a small increase in likelihood of treatment 
response for a particular individual are large. However, across 
the field of medicine in general, attempts to make pursue a 
personalised medicine approach have not fulfilled their 
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•   We have added reference to proposals that recommend 
determining whether clinically important response 
heterogeneity exists prior to quantifying it.
•   We have made it more explicit that although the underlying 
RCTs (designed to determine treatment effectiveness at the 
group level) are not single arm, machine learning algorithms 
concerned with predicting individual differences in treatment 
response are usually only trained on the active treatment arm 
data (i.e. without reference to symptom changes in the control 
arm data).
•   We have added reference to the use of ANCOVA under a 
traditional statistical framework as a way of guarding against 
regression to the mean and mathematical coupling artefacts – with 
discussion of equivalent techniques (or their absence) in the 
machine learning literature.
•   We have added reference to the possibility that appropriately 
formulated data-driven models could be used to predict 
probability of harm (symptom increase above a clinically 
significant threshold), as well as probability of successful 
treatment response (symptom decrease above some clinically 
significant threshold).
•   We have updated the manuscript to touch upon how prediction 
of differential treatment responses in future patients (i.e., out-
of-sample data) can be framed as a causal inference problem 
(with respect to current datasets) - with brief discussion of 
some pertinent issues, including representativeness of training 
data samples, and the requirement of explicit assumptions 
about the causal consequences of any confounding variables.
•   Some changes to grammar have been made throughout the 
manuscript in order to increase clarity.
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initial promise – with relatively few reaching the clinic (e.g. 9). 
Here, we explore a basic statistical issue that may limit the effec-
tiveness of this process – i.e. the validity of distinguishing between 
treatment ‘responders’ and ‘non-responders’ in the first place. We 
further discuss the reasons why this problem may be particularly 
acute in the case of available data regarding psychiatric disorders 
and chronic pain conditions, and some potential solutions.
The problem of response heterogeneity
The problem of properly identifying response heterogeneity, i.e., 
reliably distinguishing between responders and non-responders 
to a particular treatment, on the basis of randomised controlled 
trial (RCT) data, has previously been highlighted across 
various fields of medicine10–12. If not properly addressed, this 
constitutes an absolute limit on the effectiveness of predictive 
models at the level of input or training data, thereby limiting 
their future clinical usefulness.
The issue is best illustrated by considering the nature of data 
collected during RCTs, and the kind of inference this process 
affords. The foundation of an RCT is that the mean effect of an 
intervention (e.g. active drug treatment) is derived by compar-
ing what happened, on average, to the (randomly allocated) 
participants in the intervention group to what happened, on 
average, to participants in the control (e.g. placebo) arm. The 
random allocation of participants to the intervention vs control 
arms allows the control group to function as an illustration of 
what we might have expected to occur in the intervention group, 
had they not received the active treatment – in turn allowing 
us to draw conclusions about the overall (average) effects of the 
treatment itself12. Crucially, we can draw this inference only by 
direct comparison to the control arm data.
This basis of an RCT means that we cannot identify responders 
and non-responders by considering individuals in the interven-
tion group alone. In other words, it is hard to legitimately label 
an individual who received a particular active treatment as a 
‘responder’ (or not), because we do not know what would have 
happened to that particular individual if they had been in the 
comparator arm10. This kind of information is very hard to 
obtain at the individual (cf the group) level, as there is no good 
way to obtain a control observation. Formally, to properly infer 
whether a particular participant responded or didn’t respond to a 
particular treatment, we would require knowledge of what would 
have happened if a key event (treatment administration) both 
did and did not occur (a form of counterfactual reasoning), which 
is not possible in the real world11.
Although the underlying RCT datasets almost always consist 
of at least two arms (e.g. active treatment vs placebo), machine 
learning algorithms employed to predict psychiatric treatment 
response are usually trained on active treatment arm data alone 
– without reference to control arm symptom changes (e.g. 13, 14). 
Unless sufficient care is taken, these kinds of predictive models 
may therefore be the inferential equivalent of single arm trials, and 
the resultant categorisation of symptom change scores may be 
unduly influenced by sources of variance causally unrelated to 
true treatment response.
A particularly acute issue for psychiatric and chronic pain 
datasets?
Variability of change (e.g. t2 – t1 symptom score) in the interven-
tion arm is not a true estimate of variability in treatment response, 
because it includes components of within-subject variation and 
measurement error10. Even if measurement error is small (i.e. we 
can precisely measure the outcome variable of interest), for many 
medical interventions, the outcome variable will depend on a 
complex interplay of biological factors (e.g. time of day, stress 
level, etc.), and so within-subject variability will be relatively high. 
This means that the reliability of within-subject measurements 
across time points can be somewhat poor, and large variation in 
changes between study time points may be evident − even where 
there is no true individual difference in treatment response.
Unfortunately, for psychiatric and chronic pain symptom 
data, both measurement error and within-subject variation 
are likely to be high. Although self-reported symptom levels 
are considered the gold standard outcome measure for 
both psychiatric disorders and chronic pain conditions15, 
reliability is limited by factors such as cognitive capacity and 
level of insight for patient-rated measures (e.g. 16), and by 
interviewer skill and inter-rater agreement for clinician-rated 
measures (e.g. 17–19). Further, these classes of disorders 
represent episodic, chronically relapsing conditions, which will 
likely contribute to large within-subject variation, particularly 
at typical RCT follow-up timescales (often around 6 months–1 
year; cf e.g. median duration of a depressive episode of ~20 
weeks20). The greater the variation in outcome due to these 
sources, the harder to it will be to detect true individual 
differences in treatment response, under a conventional RCT 
design.
A further problem in predicting true response heterogeneity is 
susceptibility of symptom change data to regression to the mean 
and mathematical coupling artefacts21,22. Regression to the mean 
refers to the phenomenon whereby if an individual is selected on 
the basis of having an extreme measurement value at time point 
one, their second measurement value will, on average, be closer 
to the mean of the population distribution (due to the influences 
of measurement error and normal within-subject variation). 
A corollary of this effect is that t1 severity is often a significant 
covariate of change in symptom score between t1 and t2, – meaning 
that individuals with higher initial scores may appear to show 
the greatest improvement in symptom levels at follow-up, even 
when the true magnitude of change does not vary across individu-
als (see 10 for a worked example). The fact the t1 score is used to 
calculate both baseline and change scores (i.e., that they are 
mathematically coupled) results in further inflation of this 
relationship (see 22). Care should therefore be taken when key 
predictors in response algorithms closely index t1 severity, as 
this may result in a poorly generalising model. However, in 
previous studies based on psychiatric datasets, baseline severity 
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score is usually included among the features used to train 
response prediction algorithms (e.g. 13, 14, 23).
These factors may help explain why previous attempts to apply 
machine learning approaches to outcome prediction in psycho-
logical disorders have thus far had limited success in terms of 
out-of-sample (unseen data) classification. For example, a recent 
methodologically rigorous trial aiming to predict significant 
response (remission) following treatment with a particular 
antidepressant drug achieved only ~60% classification accuracy 
when the model was applied in external validation datasets14. 
However, as previously noted, tools with only modest true 
predictive value may still have reasonably high clinical utility 
compared to current best practice8; therefore this is still an 
approach very much worth pursuing.
Potential solutions
Clinical trial design
The problem of identifying true response heterogeneity is a 
problem of appropriately partitioning variance components in 
observed outcomes11. The ability to identify differential response 
to particular treatments in different individuals can be achieved 
by replication of observations at the level at which the differen-
tial response is claimed (i.e., that particular treatment in that 
particular individual). Differential treatment response (i.e., iden-
tification of patient-by-treatment interactions) can therefore be 
identified by use of repeated period cross-over designs – a form 
of trial where each participant receives both placebo and active 
treatments more than once11. However, in practice, these designs 
are rare, as they are likely to be impractical (prohibitively 
lengthy and expensive) and/or unethical. This kind of design also 
assumes that treatments wash out fully between administra-
tions, which might not be reasonable for some interventions (e.g. 
psychological therapies)24.
Training data definition and selection
An alternative approach is to improve the way data from exist-
ing RCTs is used to train predictive models. For example, it has 
been suggested that the uncertainty in each individual’s ‘response’ 
(change in symptom score in the active treatment group) could 
be expressed as a confidence interval by reference to the standard 
deviation of the change scores in the control (placebo) group 
multiplied by the appropriate value from the t distribution (e.g. 
individual change score ± 1.96*SD of control arm changes for a 
95% CI, see 24). The probability that any given individual in the 
intervention group is a true responder (true change score is greater 
than the minimum clinically significant change) can then be 
derived from individual CIs using a Bayesian approach10. Appro-
priate supervised learning algorithms could then be trained to 
predict (continuous) treatment response probability, as opposed to 
dividing individuals into binary response categories (e.g. using 
Gaussian process regression25). This approach could also be used 
to predict individual probability of harm (worsening of outcome 
measure above some minimum clinically important threshold) 
in response to a particular treatment. Some researchers have 
suggested that comparing the variances of symptom change data 
between active treatment and control arms, in order to detect 
whether there is clinically significant heterogeneity in response 
to a particular treatment in the first place, should be a pre-requisite 
for these kind of analyses10.
It also may be important to think carefully about the nature of 
the predictors (features) included in supervised learning model 
training data – as those that reference initial clinical severity 
may be vulnerable to regression to the mean-related artefacts. 
Under a traditional statistical framework, an effective way of 
dealing with these artefacts is to include baseline scores as 
covariates in models of symptom change data (i.e., conduct an 
ANCOVA). This approach can then be used to test if a given 
between-subjects variable is a significant modifier of treatment 
effect by adding it to the model (providing measurement error 
is sufficiently low24). An interesting issue is that in machine 
learning, there is not really an equivalent concept to ‘covariates 
of no interest’ – rather, model features are usually selected 
purely on the basis of their predictive capacity. One recent paper 
that explicitly addresses this problem comes from Rao and 
colleagues, who propose a method for removing known 
confounds from predictive models based on functional imaging 
data. Rao et al. suggest that one solution is to first fit linear 
models to each image feature using the confound variables 
as predictors, then consider the residuals of this model to be 
‘adjusted’ data − suitable to be used as input features for a 
confound-controlled predictive model26. There are also statisti-
cal methods that have proposed to correct for regression to the 
mean when simply correlating t2-t1 symptom changes with initial 
severity level that could be applied to training data (see 22). 
However, these may require additional measurements (e.g. 
multiple estimates of t1 value, in order to estimate measurement 
reliability).
Counterfactual probabilistic modelling and other causal 
inference methods
When a particular experiment is not feasible, an alternative 
is to train models on observational (non-experimental) data 
that are able to make counterfactual predictions – i.e. of the 
outcomes that would have been observed, had we run that 
particular experiment. For example, Saria and colleagues have 
recently developed a counterfactual Gaussian process (CGP) 
approach to modelling clinical outcome data27. The CGP is 
trained on observational symptom trajectory data to form a 
model of clinical outcomes under a series of treatments in con-
tinuous time. Crucially, the CGP is trained using a joint maximum 
likelihood objective, which parses dependencies between 
observed actions (e.g. treatments) and outcomes in order to 
infer the existence of causal relationships between the two. This 
feature allows the prediction of how future trajectories (symp-
tom levels) may change in response to different treatment 
interventions, and has previously been shown to successfully 
predict real clinical data (renal health markers following 
different kinds of dialysis,27,28).
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Thus far, the CGP has only been empirically tested as a clinical 
decision support tool on the same subjects from whom model 
training data was derived27. However, it can be argued that 
prediction of the response of future patients to particular treat-
ment options is an inference problem that does not necessarily 
involve counterfactual reasoning. Under these circumstances, we 
require a model that can infer causes that are likely to be active 
for out-of-sample data (individuals with certain features, who may 
not have received any treatment yet), as opposed to in-sample 
data (individuals whose clinical data a particular model was trained 
on, who might have showed a different response to different 
treatment strategies)29. 
This perspective raises the issue of how representative the 
individuals who make up a particular training dataset are of the 
general population (from whom future patients will be drawn). 
Importantly, concerns have previously been raised as to the 
effects of various sources of selection bias on the representa-
tiveness of participants in RCTs compared to the population at 
large30. Specific forms of selection bias that have been identi-
fied in RCTs for psychological disorders include exclusion of 
individuals with comorbidities (which for many some condi-
tions may be more common than ‘pure’ presentation), selection 
of less severe cases (e.g. in psychotic disorders, where ability to 
consent and treatment compliance may be of heightened con-
cern), or, conversely, application of minimum severity thresholds 
(e.g. in mood disorders, to reduce the likelihood of spontaneous 
remission over the trial period)31,32. Further, methods of recruit-
ment to RCTs (particularly the requirement to self-select into 
trials) may influence the distribution of various psychological 
traits in trial participants, prior to any further eligibility crite-
ria being applied (e.g. 33). Although there are methods designed 
to mitigate the effects of sample selection bias when transferring 
predictive models to a different test set (see 34), it remains an 
open question as to whether these are sufficiently robust for 
successful out-of-sample treatment prediction at the individual 
level.
The success of causal inference modelling approaches to 
response prediction may therefore depend upon availability of 
different kinds of data to that derived from traditional RCTs 
– involving semi-continuous measurement of the relevant clini-
cal outcome (both pre- and post- intervention), and gathered 
from more representative sources than some previous RCT 
datasets. Given sufficient attention to patient confidentiality 
and other ethical concerns, it may be possible to obtain 
appropriate training data from health service clinical records; 
however, frequency and consistency of symptom reporting may 
pose analytical problems (e.g. 28). The use of personal devices 
such as smartphones or other wearable technology to regularly 
self-record symptom levels may be a potential source of this 
kind of data in the future, given sufficient insight and patient 
compliance (e.g. 35).
A further important feature of predictive models derived from 
observational data is that they depend on explicit assumptions 
about the existence and causal consequences of any confounding 
variables present in the dataset. For example, the CGP approach 
requires both that there will be a consistency of outcomes between 
training observations and future outcomes, given a particular 
treatment, and that there are no important confounding vari-
ables missing from the dataset27. It will therefore be necessary 
to carefully consider how well such assumptions are met when 
considering applying these kinds of models to psychological 
and chronic pain symptom data.
Conclusions
The issues discussed above underline the importance of focus-
ing on where data comes from when considering strategies for 
personalised medicine. In particular, it is problematic to des-
ignate individual data points from a conventional RCT design 
as ‘responders’ or ‘non-responders’ to a particular treatment, 
as symptom change scores are not adjusted for other impor-
tant sources of variation. This might be particularly important 
when considering patients with episodic, chronically-relapsing 
disorders, as within-subject variability is likely to be high (and 
symptom measurement itself may be imprecise). One solution 
to this problem is to use data derived from repeated cross-over 
design clinical trials, although in practice these can be prohibi-
tively difficult and/or ethically problematic. It may be possible to 
alleviate these issues with careful training data selection and 
predictive model design, but changes in the way symptom data 
is collected and monitored may still be required in the future in 
order to maximise the clinical utility of model-aided treatment 
selection approaches.
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 of dialysis,  ).
Thus far, the CGP has only been empirically tested as a clinical decision support tool on
the same subjects from whom model training data was derived [27]. However, it can be
argued that prediction of the response of patients to particular treatment options isfuture 
an inference problem that does not necessarily involve counterfactual reasoning. Under
these circumstances, we require a model that can infer causes that are likely to be active
for  data (individuals with certain features, who may not have received anyout-of-sample
treatment yet), as opposed to data (individuals whose clinical data a particularin-sample 
model was trained on, who might have showed a different response to different treatment
strategies) [29].
This perspective raises the issue of how representative the individuals who make up a
particular training dataset are of the general population (from whom future patients will be
drawn). Importantly, concerns have previously been raised as to the effects of various
sources of selection bias on the representativeness of participants in RCTs compared to
the population at large [30]. Specific forms of selection bias that have been identified in
RCTs for psychological disorders include exclusion of individuals with comorbidities
(which for many some conditions may be more common than ‘pure’ presentation),
selection of less severe cases (e.g. in psychotic disorders, where ability to consent and
treatment compliance may be of heightened concern), or, conversely, application of
minimum severity thresholds (e.g. in mood disorders, to reduce the likelihood of
spontaneous remission over the trial period) [31,32]. Further, methods of recruitment to
RCTs (particularly the requirement to self-select into trials) may influence the distribution
of various psychological traits in trial participants, prior to any further eligibility criteria
being applied (e.g. [33]). Although there are methods designed to mitigate the effects of
sample selection bias when transferring predictive models to a different test set (see
[34]), it remains an open question as to whether these are sufficiently robust for
successful out-of-sample treatment prediction at the individual level.
The success of causal inference modelling approaches to response prediction may
therefore depend upon availability of different kinds of data to that derived from
traditional RCTs – involving semi-continuous measurement of the relevant clinical
outcome (both pre- and post- intervention), and gathered from more representative






A further important feature of predictive models derived from observational data is that
they depend on explicit assumptions about the existence and causal consequences of
any confounding variables present in the dataset. For example, the CGP approach
requires both that there will be a consistency of outcomes between training observations
and future outcomes, given a particular treatment, and that there are no important
confounding variables missing from the dataset [27]. It will therefore be necessary to
carefully consider how well such assumptions are met when considering applying these
 kinds of models to psychological and chronic pain symptom data.”
27, 28 
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vulnerable to regression to the mean-related artefacts. Under a traditional statistical
framework, an effective way of dealing with these artefacts is to include baseline scores
as covariates in models of symptom change data (i.e., conduct an ANCOVA). This
approach can then be used to test if a given between-subjects variable is a significant
modifier of treatment effect by adding it to the model (providing measurement error is
sufficiently low, [24]). An interesting issue is that in machine learning, there is not really
an equivalent concept to ‘covariates of no interest’ – rather, model features are usually
selected purely on the basis of their predictive capacity. One recent paper that explicitly
addresses this problem comes from Rao and colleagues, who propose a method for
removing known confounds from predictive models based on functional imaging data.
Rao et al. suggest that one solution is to first fit linear models to each image feature using
the  variables as predictors, then consider the residuals of this model to beconfound
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“Although the underlying RCT datasets almost always consist of at least two arms (e.g.
active treatment  placebo), machine learning algorithms employed to predictvs
psychiatric treatment response are usually trained on active treatment arm data alone –
without reference to control arm symptom changes (e.g. [13,14]). Unless sufficient care is
taken, these kinds of predictive models may therefore be the inferential equivalent of
single arm trials, and the resultant categorisation of symptom change scores may be







vulnerable to regression to the mean-related artefacts. Under a traditional statistical
framework, an effective way of dealing with these artefacts is to include baseline scores
as covariates in models of symptom change data (i.e., conduct an ANCOVA). An
interesting issue is that in machine learning, there is not really an equivalent concept to
covariates of no interest – rather, model features are selected purely on the basis of their
predictive capacity. One recent paper that explicitly addresses this issue comes from Rao
and colleagues, who propose a method for removing known confounds from predictive
models based on functional imaging data. Rao et al. suggest that a potential solution is to
first fit linear models to each image feature using the  variables as predictors,confound
then consider the residuals of this model to be ‘adjusted’ data − suitable to be used as
input features for a confound-controlled predictive model [26]. 
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